SINOVAC Biotech Ltd. ("SINOVAC") is a China-based leading biopharmaceutical company that focuses on the research, development, production, and commercialization of vaccines that protect against human infectious diseases.
More2026/11/04
On November 02, 2026, the World Health Organization (WHO) confirmed that Anflu, a trivalent split-virion influenza vaccine manufactured by SINOVAC, is prequalified. Anflu is the fourth SINOVAC vaccine
On October 14, 2026, SNA01 Injection, a Category 1 innovative drug jointly submitted for clinical trial authorization by SINOVAC and the Institute of Biophysics, Chinese Academy of Sciences (CAS), rec
2026/10/15
On September 28, SINOVAC and Egypt’s GENNVAX launched a technology transfer project for Poliomyelitis Vaccine, Inactivated, Sabin Strains (sIPV) at an event in Beijing. The launch marks the start of t
2026/09/28
The 27th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) opened in Beijing on September 22, 2026, under the theme "Transforming Innovation into Immunizati
2026/09/23
SINOVAC has undertaken nearly 60 national and regional science and technology
R&D projects; received two State Scientific and Technology Progress Awards
and three national-level institutional technology awards; and published more than
140 SCI papers, many of which were published in top academic journals including
New England Journal of Medicine, The Lancet, Science and Nature, etc.
SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive®, Influenza Vaccine (Split Virion), Inactivated - Anflu®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.